Published in Cancer Epidemiol Biomarkers Prev on November 03, 2009
Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One (2012) 1.89
Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol (2011) 1.59
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58
Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control (2009) 1.40
Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control (2010) 1.29
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One (2010) 1.28
Cholesterol and prostate cancer. Curr Opin Pharmacol (2012) 1.28
The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am (2011) 1.13
Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control (2010) 1.12
Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res (2012) 1.10
Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy. Asian J Androl (2015) 1.08
Shared common variants in prostate cancer and blood lipids. Int J Epidemiol (2014) 1.06
Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control (2011) 1.06
Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up. BMC Cancer (2012) 1.03
Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res (2011) 0.97
Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. Biochim Biophys Acta (2014) 0.97
The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control (2010) 0.97
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
The importance of LDL and cholesterol metabolism for prostate epithelial cell growth. PLoS One (2012) 0.92
Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev (2014) 0.92
Identification of androgen-regulated genes in human prostate. Mol Med Rep (2012) 0.87
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int (2014) 0.87
The diet as a cause of human prostate cancer. Cancer Treat Res (2014) 0.86
Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. Indian J Urol (2010) 0.86
Cholesterol and benign prostate disease. Differentiation (2011) 0.85
Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol (2014) 0.83
Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomarkers Prev (2009) 0.83
Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods. Asian J Androl (2015) 0.81
Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol (2013) 0.81
Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci (2014) 0.81
Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes. Ann Transl Med Epidemiol (2015) 0.80
Apolipoprotein A-I and Cancer. Front Pharmacol (2015) 0.80
LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. Am J Cancer Res (2013) 0.80
Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention. Asian J Androl (2015) 0.78
Metabolic risk factors in prostate cancer. Cancer (2010) 0.78
Cholesterol and prostate cancer risk: a long-term prospective cohort study. BMC Cancer (2016) 0.77
Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. BMC Cancer (2014) 0.77
Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Med (2016) 0.77
Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med (2016) 0.77
Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men. Lipids Health Dis (2015) 0.76
Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy. PLoS One (2015) 0.76
Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2015) 0.76
Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. Prostate (2015) 0.76
Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate Int (2016) 0.75
Association between preoperative serum total cholesterol level and biochemical recurrence in prostate cancer patients who underwent radical prostatectomy. Mol Clin Oncol (2016) 0.75
Association between Types of Chronic Conditions and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Prostate Cancer. Popul Health Manag (2016) 0.75
Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases. Endocr Relat Cancer (2016) 0.75
Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol (2015) 0.75
The Level of Serum Cholesterol is Negatively Associated with Lean Body Mass in Korean non-Diabetic Cancer Patients. Clin Nutr Res (2016) 0.75
BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. Oncotarget (2017) 0.75
Exercise-induced biochemical changes and their potential influence on cancer: a scientific review. Br J Sports Med (2016) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA (2005) 4.22
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Statin use and the risk of 10 cancers. Epidemiology (2007) 3.17
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 2.05
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol (2007) 1.97
Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis (1998) 1.95
Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.94
Cholesterol and prostate cancer. J Cell Biochem (2004) 1.92
Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev (2007) 1.91
Statins and prostate cancer risk: a case-control study. Am J Epidemiol (2005) 1.90
Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev (1997) 1.80
Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab (2008) 1.74
Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.74
Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials (2004) 1.70
Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer (2008) 1.70
Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control (2008) 1.47
Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res (1988) 1.44
Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev (1995) 1.41
Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol (1988) 1.38
Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr (2000) 1.35
Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol (1989) 1.23
Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am J Epidemiol (1993) 1.22
Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.09
Serum cholesterol and cancer in the Hypertension Detection and Follow-up Program. Cancer (1983) 1.06
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA (2013) 5.56
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Pharmacy education: back to the basics? Pharmacotherapy (2003) 4.11
Is it time to abandon the food frequency questionnaire? Cancer Epidemiol Biomarkers Prev (2005) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Genome-wide association study of circulating vitamin D levels. Hum Mol Genet (2010) 4.07
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol (2004) 3.97
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 3.51
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res (2007) 3.08
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol (2002) 3.06
Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst (2008) 3.04
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst (2006) 2.97
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer (2005) 2.91
Body mass and weight change in adults in relation to mortality risk. Am J Epidemiol (2013) 2.87
Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer (2008) 2.85
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys (2004) 2.84
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol (2002) 2.83
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol (2008) 2.83
Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA (2005) 2.71
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70